A Multicenter, Open-label Study of SI-6603 in Patients with Lumbar Disc Herniation (Phase III)
Latest Information Update: 12 Nov 2021
At a glance
- Drugs Condoliase (Primary)
- Indications Intervertebral disc degeneration
- Focus Adverse reactions; Registrational
- Sponsors Seikagaku Corporation
- 07 Mar 2018 Status changed from active, no longer recruiting to completed.
- 21 Jun 2017 This trial has been completed in Germany (end date: 17 Mar 2017).
- 15 Jun 2017 This trial has been completed in Spain (end date: 17 Mar 2017).